Guadecitabine

DRUG20 trials

Sponsors

Astex Pharmaceuticals, Inc., M.D. Anderson Cancer Center, Hoffmann-La Roche, Northwestern University, University of Southern California

Conditions

AMLAcute Myeloid LeukemiaAdvanced Kidney CancerCMMLChronic Myelomonocytic LeukemiaClear Cell Renal Cell CarcinomaColorectal AdenocarcinomaCpG Island Methylator Phenotype

Phase 1

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

CompletedNCT01261312

Astex Pharmaceuticals, Inc.AML, CMML, MDS

Start: 2011-01-04End: 2016-07-22Updated: 2025-01-23

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

CompletedNCT02892318

Hoffmann-La RocheAcute Myeloid Leukemia

Start: 2016-10-31End: 2019-12-12Target: 40Updated: 2020-03-13

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Active, not recruitingNCT02935361

University of Southern CaliforniaChronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Start: 2016-11-02End: 2027-12-31Updated: 2026-01-29

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

RecruitingNCT02998567

Royal Marsden NHS Foundation TrustNon Small Cell Lung Cancer

Start: 2017-01-26End: 2026-09-30Target: 60Updated: 2025-08-17

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT03206047

National Cancer Institute (NCI)Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +3

Start: 2017-11-08End: 2020-11-10Updated: 2025-03-13

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Active, not recruitingNCT03220477

Memorial Sloan Kettering Cancer CenterLung Cancer

Start: 2017-08-04End: 2026-07-31Updated: 2025-08-06

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Active, not recruitingNCT03257761

University of Southern CaliforniaExtrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma +25

Start: 2018-02-07End: 2026-07-31Updated: 2025-12-05

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Active, not recruitingNCT03308396

Ajjai Alva, MDAdvanced Kidney Cancer, Clear Cell Renal Cell Carcinoma, Kidney Cancer

Start: 2017-12-19End: 2023-12-31Updated: 2022-02-17

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

WithdrawnNCT03576963

University of Southern CaliforniaColorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma +5

Start: 2020-01-30End: 2023-01-30Updated: 2021-04-05

Phase 2

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

CompletedNCT02096055

M.D. Anderson Cancer CenterUntreated Adult Acute Myeloid Leukemia

Start: 2014-04-04End: 2020-11-24Updated: 2024-08-27

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

CompletedNCT02131597

M.D. Anderson Cancer CenterHigh Risk Myelodysplastic Syndrome

Start: 2014-11-10End: 2024-07-25Updated: 2025-07-17

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

CompletedNCT02684162

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome +2

Start: 2016-06-22End: 2024-10-08Updated: 2025-11-06

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CompletedNCT02901899

Northwestern UniversityRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Start: 2016-11-11End: 2023-03-31Updated: 2024-02-20

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Active, not recruitingNCT03179943

Fox Chase Cancer CenterUrothelial Carcinoma

Start: 2017-11-27End: 2022-07-31Updated: 2021-11-04

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Groupe Francophone des MyelodysplasiesAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2018-11-30End: 2022-03-31Target: 40Updated: 2018-11-15

Guadecitabine Extension Study

TerminatedNCT03603964

Astex Pharmaceuticals, Inc.Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome

Start: 2018-07-18End: 2021-10-04Updated: 2024-08-27

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

CompletedNCT03913455

Shadia Jalal, MDExtensive-stage Small Cell Lung Cancer, Small Cell Lung Cancer

Start: 2019-06-06End: 2022-02-02Updated: 2023-12-20

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Active, not recruitingNCT04340843

National Cancer Institute (NCI)Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma

Start: 2020-09-08End: 2027-01-27Updated: 2026-04-03

Phase 3

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

CompletedNCT02907359

Astex Pharmaceuticals, Inc.Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes

Start: 2017-01-13End: 2020-11-30Updated: 2024-08-27

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

CompletedNCT02920008

Astex Pharmaceuticals, Inc.Acute Myeloid Leukemia

Start: 2017-03-16End: 2020-06-01Updated: 2024-08-28

Related Papers

Abstract 4101: Blood based biomarkers of DNA methylation associated with platinum resistance in high grade serous ovarian cancer

Cancer Research2025-04-21

Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).

Journal of Clinical Oncology2024-06-013 citations

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

Blood Neoplasia2024-03-294 citations

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Cancer Immunology Immunotherapy2024-03-028 citations

Integration of CD4<sup>+</sup> T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

Cancer Science2024-02-253 citations

Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.

2024-02-016 citations

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Blood Advances2024-01-179 citations

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology2023-06-011 citations

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research2023-03-1633 citations

Final results of phase Ib/II study of durvalumab and guadecitabine in advanced clear cell renal cell carcinoma (ccRCC) and biomarker analysis.

Journal of Clinical Oncology2023-02-20

Reimagining human rights in global health: what will it take?

BMJ Global Health2022-08-0110 citations

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer

Journal of Clinical Investigation2022-06-0767 citations

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Journal for ImmunoTherapy of Cancer2022-06-0146 citations

A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers.

Journal of Clinical Oncology2022-01-1911 citations

Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors

Molecular Cancer Therapeutics2021-09-2215 citations

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology2021-05-206 citations

Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.

Journal of Clinical Oncology2021-02-206 citations

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Blood2020-11-041 citations

Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

Cancer Research2020-08-153 citations

Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.

Journal of Clinical Oncology2020-05-2010 citations

9 more papers not shown